{"id":2412,"date":"2018-05-23T00:00:00","date_gmt":"2018-05-23T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2412"},"modified":"2018-05-23T00:00:00","modified_gmt":"2018-05-23T00:00:00","slug":"wspolpraca-w-zakresie-rozwoju-lekow-z-orphazyme","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/drug-development-collaboration-with-orphazyme\/","title":{"rendered":"Wsp\u00f3\u0142praca w zakresie rozwoju lek\u00f3w z Orphazyme"},"content":{"rendered":"

CENTOGENE, \u015bwiatowy lider w wyja\u015bnianiu genetyki rzadkich chor\u00f3b dla pacjent\u00f3w, lekarzy i partner\u00f3w farmaceutycznych, og\u0142osi\u0142 dzi\u015b nawi\u0105zanie wsp\u00f3\u0142pracy w zakresie bada\u0144 klinicznych z Orphazyme A\/S (CPH: ORPHA) w celu poprawy jako\u015bci \u017cycia pacjent\u00f3w i ich rodzin cierpi\u0105cych na neuropatyczn\u0105 chorob\u0119 Gauchera \u2013 rzadk\u0105, dziedziczn\u0105, post\u0119puj\u0105c\u0105 i wyniszczaj\u0105c\u0105 lizosomaln\u0105 chorob\u0119 spichrzeniow\u0105.<\/p>\n

Zgodnie z warunkami umowy CENTOGENE wspiera wysi\u0142ki Orphazyme w zakresie bada\u0144 klinicznych w Indiach, maj\u0105cych na celu wykorzystanie ma\u0142ej cz\u0105steczki, arimoklomolu, w leczeniu neuronopatycznej choroby Gauchera.<\/p>\n

\u201cMo\u017cliwo\u015b\u0107 monitorowania post\u0119p\u00f3w leczenia w badaniu klinicznym jest obecnie kluczowa dla przemys\u0142u farmaceutycznego. Dzi\u0119ki naszemu bogatemu do\u015bwiadczeniu w identyfikacji biomarker\u00f3w i opracowywaniu narz\u0119dzi diagnostycznych, w po\u0142\u0105czeniu z nasz\u0105 dog\u0142\u0119bn\u0105 wiedz\u0105 na temat chor\u00f3b rzadkich i globalnym zasi\u0119giem, jeste\u015bmy w idealnej pozycji, aby sta\u0107 si\u0119 partnerem pierwszego wyboru dla Orphazyme i firm zajmuj\u0105cych si\u0119 rozwojem lek\u00f3w na ca\u0142ym \u015bwiecie\u201d \u2013 powiedzia\u0142 dr Arndt Rolfs, prezes i za\u0142o\u017cyciel CENTOGENE.<\/p>\n

Firma CENTOGENE jest odpowiedzialna za przetwarzanie i analiz\u0119 r\u00f3\u017cnorodnych pr\u00f3bek pochodz\u0105cych od pacjent\u00f3w uczestnicz\u0105cych w badaniu, w tym osocza, p\u0142ynu m\u00f3zgowo-rdzeniowego i suchych kropli krwi z karty CentoCard\u00ae firmy CENTOGENE. Ponadto, firma CENTOGENE opracowa\u0142a i wykorzystuje najczulszy i sprawdzony biomarker choroby Gauchera \u2013 lysoGb1 \u2013 jako narz\u0119dzie monitoruj\u0105ce w trakcie badania.<\/p>\n

O chorobie Gauchera<\/strong><\/h2>\n

Choroba Gauchera to rzadkie, dziedziczne zaburzenie metaboliczne. Z powodu braku enzymu glukocerebrozydazy, cz\u0105steczki t\u0142uszczu zawieraj\u0105ce cukier, zwane glikolipidami, gromadz\u0105 si\u0119 w lizosomach kom\u00f3rkowych. Objawy choroby Gauchera obejmuj\u0105 nieprawid\u0142owo powi\u0119kszon\u0105 w\u0105trob\u0119 i\/lub \u015bledzion\u0119 (hepatosplenomegalia), niedokrwisto\u015b\u0107 i ma\u0142op\u0142ytkowo\u015b\u0107 (trombocytopenia) oraz nieprawid\u0142owo\u015bci uk\u0142adu kostnego. Objawy s\u0105 bardzo zr\u00f3\u017cnicowane u poszczeg\u00f3lnych pacjent\u00f3w, co stanowi wyzwanie dla rozwoju klinicznego nowych terapii w tej dziedzinie. Neurologiczne aspekty choroby nie daj\u0105 jednoznacznej odpowiedzi na pytanie o jako\u015b\u0107 i oczekiwan\u0105 d\u0142ugo\u015b\u0107 \u017cycia. Oko\u0142o 10 000\u201315 000 os\u00f3b w Stanach Zjednoczonych i Europie cierpi na chorob\u0119 Gauchera.<\/p>\n

O firmie CENTOGENE<\/strong><\/h2>\n

CENTOGENE uwalnia moc wiedzy genetycznej, aby poprawi\u0107 jako\u015b\u0107 \u017cycia pacjent\u00f3w z chorobami genetycznymi. Osi\u0105gamy to dzi\u0119ki wiedzy, kt\u00f3r\u0105 zdobywamy dzi\u0119ki naszym globalnym us\u0142ugom bada\u0144 diagnostycznych, uwzgl\u0119dniaj\u0105cym globaln\u0105 r\u00f3\u017cnorodno\u015b\u0107, wiod\u0105cej na \u015bwiecie autorskiej bazie danych interpretacji genetycznej cz\u0142owieka, CentoMD\u00ae, oraz rozwi\u0105zaniom dla firm farmaceutycznych opracowuj\u0105cych leki sieroce, kt\u00f3re zmieniaj\u0105 \u017cycie.<\/p>\n

Jako jedna z najbardziej zr\u00f3\u017cnicowanych i najwi\u0119kszych na \u015bwiecie firm zajmuj\u0105cych si\u0119 testami genetycznymi, CENTOGENE stawia sobie za cel przekszta\u0142canie wiedzy genetycznej w rozwi\u0105zania i nadziej\u0119 dla pacjent\u00f3w i ich rodzin.<\/p>\n

www.centogene.com<\/a> www.centoMD.com<\/a> <\/p>\n

O firmie Orphazyme A\/S<\/strong><\/h2>\n

Orphazyme to firma biofarmaceutyczna, kt\u00f3rej celem jest dostarczanie innowacyjnych terapii pacjentom z rzadkimi chorobami zagra\u017caj\u0105cymi \u017cyciu lub powoduj\u0105cymi niepe\u0142nosprawno\u015b\u0107. Nasze badania koncentruj\u0105 si\u0119 na opracowywaniu terapii chor\u00f3b spowodowanych nieprawid\u0142owym fa\u0142dowaniem bia\u0142ek i dysfunkcj\u0105 lizosom\u00f3w. Arimoklomol, g\u0142\u00f3wny kandydat firmy, jest w fazie bada\u0144 klinicznych w leczeniu czterech chor\u00f3b rzadkich: choroby Niemanna-Picka typu C, choroby Gauchera, sporadycznego wtr\u0119towego zapalenia mi\u0119\u015bni (IMZS) oraz stwardnienia zanikowego bocznego. Firma z siedzib\u0105 w Danii jest notowana na gie\u0142dzie Nasdaq Copenhagen (ORPHA.CO). Wi\u0119cej informacji mo\u017cna znale\u017a\u0107 na stronie internetowej.  www.orphazyme.com<\/a> <\/p>","protected":false},"excerpt":{"rendered":"

CENTOGENE og\u0142asza wsp\u00f3\u0142prac\u0119 z Orphazyme w zakresie rozwoju lek\u00f3w na neuropatyczn\u0105 chorob\u0119 Gauchera<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2412","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nDrug development collaboration with Orphazyme | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/wspolpraca-w-zakresie-rozwoju-lekow-z-orphazyme\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug development collaboration with Orphazyme | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/wspolpraca-w-zakresie-rozwoju-lekow-z-orphazyme\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-23T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"Drug development collaboration with Orphazyme\",\"datePublished\":\"2018-05-23T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\",\"name\":\"Drug development collaboration with Orphazyme | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2018-05-23T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug development collaboration with Orphazyme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wsp\u00f3\u0142praca w zakresie rozwoju lek\u00f3w z Orphazyme | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/wspolpraca-w-zakresie-rozwoju-lekow-z-orphazyme\/","og_locale":"pl_PL","og_type":"article","og_title":"Drug development collaboration with Orphazyme | CENTOGENE","og_description":"CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease","og_url":"https:\/\/www.centogene.com\/pl\/wspolpraca-w-zakresie-rozwoju-lekow-z-orphazyme\/","og_site_name":"CENTOGENE","article_published_time":"2018-05-23T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"2 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"Drug development collaboration with Orphazyme","datePublished":"2018-05-23T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/","url":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/","name":"Wsp\u00f3\u0142praca w zakresie rozwoju lek\u00f3w z Orphazyme | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2018-05-23T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"Drug development collaboration with Orphazyme"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2412"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}